BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 5
• 6
• 7
• 8
• 9
• 10
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 24
• 26
• 27
• 28
• 29
• 30
• 31

• Press Releases

  Ardelyx to Report Third Quarter 2025 Financial Results on October 30, 2025

  October 14, 2025

   · 

  1 min read
• Press Releases

  4DMT Advances 4D-710 to Phase 2 with Additional Funding and Support from the Cystic Fibrosis Foundation

  October 14, 2025

   · 

  9 min read
• Press Releases

  Apyx Medical Corporation Submits FDA 510(k) for Device Label Expansion of AYON Body Contouring System™ for Power Liposuction

  October 14, 2025

   · 

  6 min read
• Press Releases

  Soleno Therapeutics Appoints Biopharmaceutical Executive Mark W. Hahn to its Board of Directors

  October 14, 2025

   · 

  5 min read
• Press Releases

  Waters Launches Charge Detection Mass Spectrometry Technology to Accelerate the Development of Next-Generation Biotherapeutics

  October 14, 2025

   · 

  4 min read
• Press Releases

  Theriva™ Biologics Announces Upcoming Presentations at Medical Meetings

  October 14, 2025

   · 

  5 min read
• Press Releases

  Immutep Announces Successful Completion of FDA Project Optimus Requirements

  October 14, 2025

   · 

  3 min read
• Press Releases

  Cidara Therapeutics to Present Late-Breaking Clinical Phase 2 Data on CD388 at ID Week 2025

  October 14, 2025

   · 

  1 min read
• Press Releases

  SELLAS Life Sciences to Present In Vivo Preclinical Data Demonstrating Statistically Significant Survival Benefit of SLS009 in T-Cell Prolymphocytic Leukemia at the European Society for Medical Oncology (ESMO) Congress 2025

  October 14, 2025

   · 

  5 min read
• Press Releases

  MannKind Announces U.S. FDA Accepts for Review its Supplemental Biologics License Application (sBLA) for Inhaled Insulin (Afrezza) in Children and Adolescents Aged 4-17 Years Living with Diabetes

  October 14, 2025

   · 

  4 min read